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We have studied 23 children from 13 families with a clinical diagnosis of Aicardi-Goutie`res syndrome. Affected
individuals had developed an early-onset progressive encephalopathy that was characterized by a normal head
circumference at birth, basal ganglia calcification, negative viral studies, and abnormalities of cerebrospinal fluid
comprising either raised white cell counts and/or raised levels of interferon-a. By means of genomewide linkage
analysis, a maximum-heterogeneity LOD score of 5.28 was reached at marker D3S3563, with , where a isa = .48
the proportion of families showing linkage. Our data suggest the existence of locus heterogeneity inAicardi-Goutie`res
syndrome and highlight potential difficulties in the differentiation of this condition from pseudo-TORCH (toxo-
plasmosis, rubella, cytomegalovirus, and herpes simplex virus types 1 and 2) syndrome.
In 1984, Jean Aicardi and Franc¸oise Goutie`res described
eight children with an early-onset progressive encepha-
lopathy characterized by basal ganglia calcification, leu-
kodystrophy, chronic cerebrospinal fluid (CSF) lympho-
cytosis, and negative serological investigations for
common prenatal infections (Aicardi-Goutie`res syn-
drome [MIM 225750]; Aicardi and Goutie`res 1984).
The observation of familial cases, affected females, and
parental consanguinity prompted the authors to propose
that the condition was inherited as an autosomal reces-
sive trait. Further reports (Giroud et al. 1986; Mehta et
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al. 1986; Diament et al. 1986; Bo¨nnemann and Mei-
necke 1992; Tolmie et al. 1995; Verrips et al. 1997;
Kumar et al. 1998; McEntagart et al. 1998; Goutie`res
et al. 1998; Østergaard et al. 1999) have supported this
conclusion. These findings, taken together with the iden-
tification of families with affected siblings who are sep-
arated in age by a number of years and in birth order
by intervening normal children, challenge the possibility
that Aicardi-Goutie`res syndrome could result solely as
a consequence of occult embryopathic infection. How-
ever, it was the resemblance of the clinical phenotype of
Aicardi-Goutie`res syndrome to the sequelae of congen-
ital infection that led to the measurement of interferon-
a (IFN-a) in children with the disease (Lebon et al.
1988). A report of raised levels of CSF IFN-a in 14/15
patients with Aicardi-Goutie`res syndrome suggests a
close association between this parameter and the other
clinical and laboratory features (Goutie`res et al. 1998),
such that an elevation of CSF IFN-a in the absence of
Table 1
Clinical Characteristics of 23 Affected Individuals
FAMILY/
PATIENT
AGE AT
PRESENTATION
(mo)
OCCIPTIOFRONTAL CIRCUMFERENCEa
BRAIN
CALCIFICATIONb
WHITE-MATTER
HYPODENSITIESc
CSF WCCd/mm3
[% LYMPHOCYTES]
(AGE)
IFN-a IU/LITER
IN [CSF/SERUM]e
(AGE)At Birth (Gestational age) After Birth (Age)
1/V:1 4 30 cm (36 wk) 37.5 cm (6 mo) BG, DN, WM  60 [50] (6 mo) NA
1/V:2 4 32.5 cm (38 wk) 40 cm (36 mo) BG, WM Unknown 52 (1 mo) NA
2/V:1 1 33.5 cm (37 wk) 4 SD (12 mo) BG (trace) Minimal !5 (1 mo) 200 IU/liter [NA] (1 mo)
2/V:2 1 34 cm (40 wk) 2 SD (6 mo) BG  !5 (6 mo) 12 IU/liter [25 IU/liter] (6 mo)
3/IV:1 1 “Normal” 42 cm (14 mo) BG, DN, WM f !5 (12 mo and 18 mo) 50 IU/liter [50 IU/liter] (12 mo)
4/II:1 1 33 cm (37 wk) 41.5 cm (11 mo) Not on MRI  NA NA
4/II:2 1 35 cm (40 wk) 43 cm (10 mo) BG, DN Unknown 27 (6 mo) 100 IU/liter [NA] (6 mo)
5/V:1 4 36 cm (40 wk) 41 cm (12 mo) BG  38 [40] (3 mo); 27 [60] (8 mo) 50 IU/liter [200 IU/liter] (3 mo)
6/II:1 !1 35 cm (40 wk) 45 cm (93 mo) BG, WM Unknown 9 [70] (60 mo) 6 IU/liter [NK] (60 mo)
6/II:2 !1 34 cm (40 wk) 41 cm (46 mo) WM  23 (2 mo); 52 [70] (4 mo);
14 [80] (24 mo)
9 IU/liter [NK] (24 mo)
7/II:1 2 35.6 cm (40 wk) 46 cm (42 mo) BG, WM  54 [99] (2 mo) NA
7/II:2 1 35 cm (40 wk) 40.8 cm (5 mo) BG, DN  17 [67] (13 mo) NA
8/IV:1 8 “Normal” 49 cm (60 mo) BG  14 (13 mo) NA
8/IV:2 12 “Normal” 52 cm (36 mo) BG  550 [75] (30 mo) NA
9/IV:2 8 “Normal” 40.9 cm (9 mo) BG Unknown 0 (84 mo) !2 IU/liter [!2 IU/liter] (84 mo)
9/IV:3 6 50th percentile (34 wk) 41.5 cm (9 mo) BG Unknown 4 (11 mo) 3 IU/liter [!2 IU/liter] (11 mo)
10/IV:1 7 35.5 cm (40 wk) 54 cm (108 mo) BG  16 (12 mo); 8 (108 mo) !2 IU/liter [!2 IU/liter] (108 mo)
10/IV:3 !12 34.5 cm (40 wk) 47 cm (21 mo) BG  13 (12 mo); 13 (21 mo) 25 IU/liter [!2 IU/liter] (21 mo)
11/II:1 1 33 cm (40 wk) 6 SD (36 mo) BG, WM  25 (10 mo) 25 IU/liter [50 IU/liter] (10 mo)
11/II:2 2 34 cm (40 wk) 45.5 cm (22 mo) BG, DN Not obvious 10 (2 mo) 37 IU/liter [12 IU/liter] (2 mo)
12/II:2 !1 34 cm (40 wk) !.4th percentile (6 mo) BG, WM  60 [70] (2 mo) NA
13/II:1 6 38 cm (40 wk) 1 SD (60 mo) BG Unknown 38 (6 mo) 25 IU/liter [NA] (6 mo)
13/II:2 2 35 cm (40 wk) 4 SD (12 mo) BG, WM Unknown 44 (2 mo) NA
a SD = standard deviations below mean.
b BG = basal ganglia; DN = dentate nuclei; WM = white matter; MRI = magnetic-resonance imaging.
c A plus sign () denotes presence.
d WCC = white cell count.
e NA = not assessed.
f Marked.
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Table 2
Maximum Two-Point LOD Score at
Each Marker, under the Hypothesis
of Locus Homogeneity
Marker
Maximum Total
Two-Point
LOD Score v
D3S3038 .02 .3
D3S2432 .13 .2
D3S1768 .05 .4
D3S3527 2.18 .1
D3S3559 1.73 .1
D3S3563 1.85 .1
D3S1289 .95 .1
D3S3721 .33 .3
D3S1300 .01 .4
Table 3
Multipoint LOD Score at Specified Markers, for Each Family
FAMILY
NUMBER
MULTIPOINT LOD SCORE AT MARKER
D3S1768 D3S3527 D3S3559 D3S3563 D3S1289
1 2.95 2.97 2.98 2.98 2.96
2 .06 1.29 1.86 1.86 1.86
3 .05 1.14 1.19 1.19 1.19
4 .60 .60 .60 .60 .47
5 .22 .70 .99 1.00 1.01
6 1.20 .03 .60 .60 .59
7 .59 .58 .54 .54 .52
8 4.44 3.15 4.30 4.32 8.80
9 8.40 7.60 7.80 7.00 7.14
10 4.93 4.65 5.90 6.16 4.04
11 2.80 1.80 2.31 3.13 3.08
12 .09 1.17 1.18 1.18 1.17
13 .90 2.90 3.05 2.59 3.22
infection is currently considered to be a marker for the
condition (Goutie`res 2000).
Intrafamilial phenotypic variability was recognized in
the initial description of Aicardi-Goutie`res syndrome
and has since been confirmed (Aicardi and Goutie`res
1984; Goutie`res et al. 1998). Patients with apparently
static or slowly progressive encephalopathy are on rec-
ord (Verrips et al. 1997; McEntagart et al. 1998), and,
importantly, discordance for the presence of CSF pleo-
cytosis has been described (Østergaard et al. 1999).
These reports raise fundamental questions regarding the
definition of Aicardi-Goutie`res syndrome and its dis-
tinction from pseudo-TORCH (toxoplasmosis, rubella,
cytomegalovirus, and herpes simplex virus types 1 and
2) syndrome (MIM 251290) (Baraitser et al. 1983; Ish-
itsu et al. 1985; Burn et al. 1986; Bolthauser et al. 1991;
Reardon et al. 1994; Monastiri et al. 1997; al-Dabbous
et al. 1998). Both conditions share an early-onset en-
cephalopathy with basal ganglia calcification, leukoen-
cephalopathy, and brain atrophy. They are said to differ
because of the presence, in pseudo-TORCH syndrome,
of congenital microcephaly, neonatal disturbance of liver
function, thrombocytopenia, and a normal CSF exam-
ination, although this latter finding has only been re-
ported in a minority of described cases. However, in a
recent review of 27 patients with Aicardi-Goutie`res syn-
drome, two children showed a prenatal microcephaly,
one exhibited a neonatal thrombocytopenia, two had
hepatosplenomegaly, and three had transient elevation
of liver enzymes, with one child undergoing liver biopsy
(Goutie`res et al. 1998). These findings, together with the
observations of Østergaard et al. (Østergaard et al.
1999), the absence of CSF IFN-a measurements in pa-
tients described with pseudo-TORCH syndrome, and
the identification of cases showing clear overlap between
that disease and Aicardi-Goutie`res syndrome (Stephen-
son et al. 1997), suggest the possibility that these clinical
phenotypes may represent a single disorder.
In the present study, we report the results of linkage
studies in 23 children from 13 families who were affected
with Aicardi-Goutie`res syndrome. Our results demon-
strate significant linkage to chromosome 3p21 in a pro-
portion of the families and suggest the existence of at
least one additional disease locus.
All affected singletons and at least one sibling from
every family in which more than one child was affected
fulfilled inclusion criteria by showing: (1) a progressive
neurological disorder with onset in the first year of life;
(2) a normal head circumference at birth; (3) calcification
involving the basal ganglia and sometimes extending to
the white matter; (4) a CSF pleocytosis (15 cells/mm3)
and/or a raised level of CSF IFN-a (12 IU/liter); and (5)
negative TORCH studies. Details for all subjects are
given in table 1, and clinical descriptions of five of these
families (families 2 and 8–11) have been published else-
where (Tolmie et al. 1995; Stephenson et al. 1997; Ver-
rips et al. 1997; Kumar et al. 1998; McEntagart et al.
1998). Families 1–3 and 8–11 were genotyped in an
initial genome search, and the remaining families were
analyzed with markers in regions of interest.
The Cooperative Human Linkage Center Human
Screening Set/Weber version 8 (Research Genetics) was
used in an autosomal genomewide search. This panel
contains 386 microsatellite repeat markers spaced at
∼10-cM intervals, with an average heterozygosity of .76.
PCR amplification of all markers was performed ac-
cording to the manufacturer’s specifications, by use of
a Roboseq 4200 (MWG BioTech). Amplified markers
were pooled and electrophoresed on an ABI Prism 377
gene sequencer (PE Biosystems) with 4.2% polyacryl-
amide gels at 3,000 V and 52C for 2.5 h. Fragment-
length analysis was undertaken with the use of the ABI
Prism GENESCAN and GENOTYPER 1.1.1 analysis
packages. For fine mapping on chromosome 3p, five
polymorphic markers were selected from the Genome
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Figure 1 Graph of multipoint HLOD scores against distance (in cM) from 3pter. Maximum HLOD = 5.28, with . Confidencea = .48
limits are given as 1-LOD-unit and 3-LOD-unit support intervals
Table 4
HOMOG Analysis of Multipoint Data
Hypothesisa df x2
Likelihood
Ratio
H2 vs. H1 1 24.232 1.82 # 105
H1 vs. H0 1 .000 1.00
H2 vs. H0 2 24.232 1.82 # 105
a H0 = no linkage; H1 = linkage, homo-
geneity; H2 = linkage, heterogeneity.
Database: tel-D3S1768-D3S3527-D3S3559-D3S3563-
D3S1289-cen. Information regarding marker order and
relative distances was obtained from linkage maps from
the Center for Medical Genetics, Marshfield Medical Re-
search Foundation. An autosomal recessive mode of in-
heritance with 95% penetrance was assumed. The dis-
ease-allele frequency was estimated to be 1/500. For
markers used in the initial genome screen, equal allele
frequencies were calculated on the basis of the observed
number of alleles with a lower frequency set at .1. For
further analysis of the candidate region, marker fre-
quencies were calculated from transmitted and nontrans-
mitted parental alleles with a minimum frequency set at
.1. Pedigree-allele inconsistencies were identified with the
use of PedCheck (O’Connell and Weeks 1998). Two-
point analysis was performed using the LINKAGE anal-
ysis programs (Lathrop et al. 1984). Multipoint LOD
scores were computed by means of the GENEHUNTER
program, version 2.0 beta (Kruglyak et al. 1996). Het-
erogeneity testing was performed with the use of GENE-
HUNTER and HOMOG, version 3.33 (Morton 1956;
Ott 1991). The study was approved by the Leeds Health
Authority/United Teaching Hospitals National Health
Service Trust Research Ethics Committee.
After an initial genome scan, no single region com-
patible with linkage in all families could be determined.
However, heterogeneity analysis of the linkage data iden-
tified two regions with a multipoint heterogeneity LOD
(HLOD) score 12 (data not shown). The addition of
further marker information left a single locus, on chro-
mosome 3p21, with an HLOD score greater than this
value. Under the hypothesis of locus homogeneity, link-
age analysis of the complete pedigree set gave a maxi-
mum two-point LOD score of 2.18 (recombination frac-
tion [v] = 0.1) at D3S3527 (table 2). Multipoint analysis
using the hypothesis of locus homogeneity produced
negative values (maximum LOD 7) between D3S3038
and D3S1300, but seven families had positive individual
LOD scores in this region (table 3). In contrast, under
an assumption of locus heterogeneity, a maximum mul-
tipoint HLOD score of 5.28 was obtained at D3S3563,
with , where a is the proportion of families show-a = .48
ing linkage (fig. 1). The results of both haplotype in-
spection (fig. 2) and heterogeneity testing of the multi-
point data by use of HOMOG (tables 4 and 5) were
consistent with these findings. The highest multipoint
LOD score for an individual pedigree was reached in
family 1 (LOD 2.98; table 3) and is based on the presence
of a homozygous region in one child (patient V:1) and
the transmission of a common haplotype to patient V:
2 (fig. 2). Although no corresponding region of homo-
zygosity could be identified in patient V:2, this finding
is in keeping with the results of a genealogy search that
failed to identify any common ancestry between indi-
viduals IV:3 and IV:4. The other families showing results
consistent with linkage at this position included a Pak-
istani sib pair, a Pakistani singleton, a Turkish singleton,
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Table 5
HOMOG Analysis: Conditional Probability
of Linkage to AGS1, by Family
FAMILY
NUMBER
CONDITIONAL
PROBABILITY
OF LINKAGE
1-LOD-UNIT
SUPPORT
INTERVAL
Lower Upper
1 .99 .99 .99
2 .98 .91 .99
3 .94 .73 .98
4 .79 .28 .93
5 .91 .52 .98
6 .80 .39 .94
7 .78 .37 .93
8 .00 … …
9 .00 … …
10 .00 … …
11 .00 … …
12 .06 .01 .2
13 .00 … …
Table 6
Details of Extraneurological Features Noted in Affected Individuals
Family/
Patient Neonatal Thrombocytopenia HSa Asymptomatic Elevation of Liver Enzymes
Chilblain-Like
Lesions
1/V:1    
1/V:2 Purpura and bruising   
2/V:1 Platelets 32 # 109/liter (at birth) and 100 # 109/liter (at
age 3 wk); bone marrow normal
 ALT 126 and AST 177 (at age 2 mo) 
2/V:2    
3/IV:1 Platelets 59 # 109/liter (at birth) and normal (by age 6 mo)  ALT 207 and bilirubin 13 (at age 6 mo) 
4/II:1    
4/II:2    
5/V:1 Platelets 103 # 109/liter (at age 9 wk)   
6/II:1    b
6/II:2 Platelets 111 # 109/liter (at age 2 d)   
7/II:1    
7/II:2    
8/IV:1    
8/IV:2    
9/IV:2    
9/IV:3    
10/IV:1    
10/IV:3    
11/II:1    
11/II:2   AST 172 and ALT 251 (at age 6 wk) 
12/II:2    
13/II:1   ALT 400 and AST 170 (at age 18 mo) 
13/II:2    
NOTE.—A plus sign () denotes presence; a minus sign () denotes absence.
a Hepatosplenomegaly.
b Treated with steroids.
and three white sib pairs. When the results from these
seven families are combined, the minimum critical re-
gion—that is, the smallest region that is found to be
identical by descent in affected children from consan-
guineous matings and that is also overlapped by the
common haplotype in patient V:2 in family 1 and by
regions of concordance in affected siblings from non-
consanguineous pedigrees—would lie between D3S3527
and D3S3721 and would cover a genetic distance of ∼12
cM. However, the 3-LOD-unit support interval defines
a distance that is considerably larger than this (fig. 1).
We have followed the recommendation of Terwilliger
and Ott, in setting the threshold value of 3.3 for a HLOD
score, to declare significant linkage in the presence of
locus heterogeneity (Terwilliger and Ott 1994). On this
basis, our data establish the existence of a locus, AGS1,
for Aicardi-Goutie`res syndrome on chromosome 3p and
suggest that mutations in at least one other gene produce
a similar phenotype. Careful comparison of the clinical
and biological characteristics of families with or without
putative linkage in this study failed to identify any ob-
vious differentiating features. We consider locus hetero-
geneity to be the most likely explanation for difficulties
in identification of genetic linkage experienced elsewhere
(Faure´ et al. 1999).
We note that, in two of the seven families showing
results compatible with linkage to AGS1, affected in-
dividuals did not demonstrate a CSF lymphocytosis,
which is a feature that was previously considered to be
mandatory for the diagnosis of Aicardi-Goutie`res syn-
drome. However, the recent description of female sib-
lings that were affected with clinically typical disease but
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Figure 2 Pedigrees showing linkage (families 1–7) and pedigrees not showing linkage (families 8–13), as assigned by HOMOG analysis,
with the most-likely haplotypes for region of interest on chromosome 3p. Unaffected children that were not genotyped have been excluded
from the pedigrees displayed.
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were discordant for the presence of a chronic CSF pleo-
cytosis suggests that this feature is not always present
(Østergaard et al. 1999). Moreover, the affected children
in these families (families 2 and 3) had raised levels of
IFN-a in the CSF—a recognized marker for Aicardi-
Goutie`res syndrome—and a normal head circumference
at birth, which would be atypical for pseudo-TORCH
syndrome. Although it is not possible to definitively cat-
egorize such cases showing overlap between the two con-
ditions, we consider our clinical and genetic data to add
weight to the previous assertion that some cases of Ai-
cardi-Goutie`res syndrome and pseudo-TORCH syn-
drome may represent the same disorder (Stephenson et
al. 1997).
A number of extraneurological features were observed
in our patients (table 6). It is of note that discordance
for each of these findings was present within at least one
sib pair. All of these features have previously been de-
scribed in Aicardi-Goutie`res syndrome (Goutie`res et al.
1998), and they highlight again the possibility for mis-
diagnosis of congenital infection. Interestingly, vasculitic
lesions bearing similarity to the chilblains seen in Ai-
cardi-Goutie`res syndrome (Tolmie et al. 1995; Stephen-
son et al. 1997) have been reported during treatment
with IFN-a (Bachmeyer et al. 1996; Creutzig and Freund
1996; Campo-Voegeli et al. 1998; Cid et al. 1999).
The development of transgenic mice with astrocyte-
targeted chronic overproduction of IFN-a showing neu-
ropathologic features that mimic those found in Aicardi-
Goutie`res syndrome (Akwa et al. 1998; Goutie`res et al.
1998; Kumar et al. 1998; Barth et al. 1999; Campbell
et al. 1999) suggests a direct causal relationship between
abnormal intrathecal synthesis of this cytokine and the
disease. We hypothesize that the elevated levels of IFN-
a seen in Aicardi-Goutie`res syndrome may result from
loss of function of a normal repressor of IFN-a pro-
duction, but, although the mechanism of cytokine signal
generation is well understood, little is known about the
mechanisms of signal attenuation (Foster and Finter
1998; Schindler 1999). Unfortunately, although 170
genes and many more partial transcripts map between
markers D3S3527 and D3S3721, none are as yet rec-
ognized as being directly involved in IFN-a metabolism.
In summary, genomewide linkage analysis of 23 chil-
dren with Aicardi-Goutie`res syndrome has identified a
locus for the disorder on chromosome 3p and has sug-
gested the existence of locus heterogeneity. We speculate
that classification of the group of genetic conditions
masquerading as the sequelae of congenital infection is
likely to require adjustment as the responsible genes are
characterized.
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